How is prescription drug manufacturing equipment appraised?
Through sales comparison and cost approaches: tablet presses, blister packers, and filling lines are valued from comparable sales in pharmaceutical and process equipment auctions and surplus dealer inventories, cross-checked against replacement cost new less depreciation. Income capitalization is rarely applied to individual machines because production income cannot credibly be tied to one asset inside an operating facility.
Does cGMP compliance status affect pharmaceutical equipment value?
Yes. Whether a machine still meets current FDA cGMP and validation standards materially affects its effective age and its functional and economic obsolescence, and therefore the depreciation taken from replacement cost new. Year of manufacture, usage hours, and maintenance records feed the same calculation. Equipment that cannot be validated for current production may carry heavy obsolescence adjustments no matter how clean it looks.
Can pharma equipment be valued from the income it generates?
Rarely, and blanket recommendations to capitalize production income do not reflect accepted practice. Attributing revenue to a specific machine in a GMP facility is difficult and impractical, which is why professional standards note that sales comparison and cost approaches handle nearly all equipment assignments. A credible report documents that the income approach was considered and explains why it was not applied.
What separates a defensible pharmaceutical equipment appraisal from a weak one?
Verified comparables with documented adjustments, and a reconciliation of the value indications into a supported conclusion. Weak reports list a few asking prices without verification, skip adjustments for age, capacity, or regulatory compliance, and never explain how the final number was reached. Each asset should be identified by make, model, serial number, and capacity; vague identification is itself a red flag for auditors and courts.